What is InMed’s mission? In this interview with Shadd Dales of The Dales Report, InMed CEO, Eric A. Adams, talks about InMed’s pharmaceutical programs and expansion into the health and wellness sector with the recent acquisition of rare cannabinoid manufacturer, BayMedica.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should